Quarterly Result12 Aug 2025, 02:47 pm
Fermenta Biotech Ltd. Reports 39% Revenue Surge in FY25, Achieves Robust Financial Turnaround
AI Summary
Fermenta Biotech Ltd. has reported a surge in consolidated revenue to X481 crore, a 39% increase from X347 crore in FY24, at its 73rd Annual General Meeting (AGM). The company has restored profitability with an EBITDA of X122 crore and a net profit of X76 crore, compared to a net loss in the prior year. The turnaround spans Fermenta’s financials, operations, and strategy. Recent highlights include manufacturing and technology breakthroughs, backward integration, strategic growth in human nutrition innovations, and global recognition.
Key Highlights
- Consolidated revenue surged to X481 crore, up 39% from X347 crore in FY24
- Restored profitability with EBITDA of X122 crore and net profit of X76 crore versus prior year net loss
- Manufacturing and technology breakthroughs, including plant-source Vitamin D3
- Backward integration and strategic growth in human nutrition innovations
- Global recognition and certifications from GAIN, WFP Biotech GmbH EUGMP, and US FDA